The chemoinformatics market is expected to grow at a CAGR of 15.6% during the forecast period of 2025 to 2033. It is a crucial component of the pharmaceutical and chemical industries, is poised for substantial growth from 2025 to 2033. This expansion is driven by several key factors, including advancements in chemical analysis, drug discovery, and molecular modeling. The market plays a pivotal role in streamlining research processes, reducing costs, and accelerating the development of new compounds.
The healthcare decision support and IBM Watson market is projected to showcase steady growth at a compounded annual growth rate (CAGR) of 11.4% during the forecast period from 2018 to 2026. IT-healthcare segment has undergone tremendous revolution in the last decade providing solutions such as pharmacovigilence, clinical data management, regulatory affairs, scientific journal publications etc.
The antimicrobial susceptibility test market had market size of US$ 2885.42 Mn in 2021 and will grow at a CAGR 4.7% and is anticipated to reach US$ 4354.68 Mn in 2033. World Health Organization (WHO) has stipulated stringent guidelines to life science industry and agriculturists to judiciously use antibiotics. Rising prevalence of infectious disease and looming threat of superbug infection drives the antimicrobial susceptibility market growth.
The global cDNA and oDNA microchips market is growing effectively, was valued at US$ 547.2 Mn in 2020 and expected to reach US$ 1254.0 Mn by 2029. The global market is growing productively at a CAGR of 9.7% during the forecast period. Incorporation of new technologies in the biological and electronic component of microchips is enhancing the overall growth globally. Advancement in nanotechnology, clinical diagnostics, cancer research, and agriculture also reflects favorable growth during the forecast period. High global prevalence of cancer provides major opportunity in the global market.
The global proteomics market held US$ 19.81 Bn in 2020 and expected to grow at compound annual growth rate (CAGR) of 10.4% during the forecast period from 2021 to 2029. The market is fueled by the growing importance of sensitive and accurate diagnosis offered by proteomics in personalized medicine. Detailed study of proteins provides superior understanding and opportunities for the development of drugs that can target disease pathways more efficiently.
The global Medical biosensors market is growing productively, was valued at US$ 9.2 Bn in 2017 and expected to reach US$ XX Bn by 2026. New technology assessment in the biological and electronic component of a biosensor in the portable devices is enhancing the overall growth significantly.
Computational biology is an interdisciplinary science that is being persistently advancing through the previous decades by using the power of mathematics and computation. The primary aim of computational biology is to employ large-scale computational methods to the fields of cellular, structural and molecular biology for answering emerging biological questions which were earlier not possible to be tackled with traditional approaches.
The cell surface markers market is set to reach US$ 33,712.7 Mn by 2026 from US$ 16,586.7 Mn in 2017 showcasing progressive growth at a compound annual growth rate (CAGR) of 8.2% during the forecast period from 2018 to 2026. Technological advancements in the production of monoclonal antibodies and manufacturing of cell specific antibodies for disease diagnosis and prognosis are the major factors to drive the cell surface markers market.
The global artificial intelligent (AI) in healthcare market is primarily driven by the increasing usage of big data in healthcare sector and advantage of AI to improve the imbalance among the healthcare professionals and patients, augment patient outcomes and aid in clinical trial simulation and development process.
Drug discovery is a process wherein new drugs are identified for any disease indication. Developing drug from the stage of discovery to market approval is a lengthy process which contribute to significant costs to the developers. Main focus of R&D is into identification of a target and discovery of some chemical candidates which can activate or block the target. The main reasons of drug failure are lack of efficacy and safety of discovered drug candidate, leading to financial losses to the companies. To inhibit such contingencies, the status of efficient drug discovery process have become critical in the field of drug development.
The drug discovery market plays a critical role in the pharmaceutical industry, which is focused on the discovery, development, and commercialization of new drugs for the treatment of diseases. The drug discovery process involves identifying and validating new drug targets, developing and optimizing lead compounds, and conducting preclinical and clinical studies to evaluate safety and efficacy. One of the primary drivers of the drug discovery market is the increasing prevalence of diseases worldwide. Chronic diseases such as cancer, diabetes, and cardiovascular diseases are a significant burden on healthcare systems globally. There is an urgent need for new and effective therapies to treat these diseases, which has led to the growth of the drug discovery market. The global drug discovery market is expected to grow at a CAGR of 10.5% during the period of 2023 to 2031. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years.
One of the emerging trends in the drug discovery market is the use of artificial intelligence (AI) and machine learning (ML). AI and ML technologies can accelerate the drug discovery process by analyzing large amounts of data and identifying potential drug targets and lead compounds. These technologies can also be used to optimize drug development processes, such as clinical trial design and patient selection. Another trend in the drug discovery market is the use of genomics and proteomics. Genomics and proteomics technologies can identify new drug targets and improve the understanding of disease biology. These technologies can also be used to develop personalized medicine, which involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles.
The increasing focus on personalized medicine is also driving the growth of the drug discovery market. Personalized medicine involves developing treatments that are tailored to individual patients based on their unique genetic and molecular profiles. This approach has the potential to improve patient outcomes and reduce healthcare costs by providing more effective and targeted treatments. The development of personalized medicine requires the use of advanced drug discovery technologies, which has contributed to the growth of the drug discovery market. The increasing focus on rare diseases is driving the growth of the drug discovery market. Rare diseases are defined as diseases that affect fewer than 200,000 people in the United States. Although each rare disease affects a small number of people, there are over 7,000 rare diseases, which together affect millions of people worldwide. There is an urgent need for new therapies to treat rare diseases, which has led to the growth of the drug discovery market.
The drug discovery market is a critical component of the pharmaceutical industry, providing innovative solutions for the discovery, development, and commercialization of new drugs. The increasing prevalence of diseases worldwide, advancements in technology, and the emerging trends in AI and ML, genomics and proteomics, personalized medicine, and rare diseases are expected to drive the growth of the drug discovery market. As the demand for new and effective therapies continues to increase, the drug discovery market is expected to remain a critical component of the pharmaceutical industry in the coming years. Companies that provide drug discovery services are well-positioned to capitalize on this growing market.
